Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service carotid revascularization cases in Texas: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 6% on average (200 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 107 | 3,962 | 44% |
| 2020 | 73 | 3,224 | 47% |
| 2021 | 79 | 3,161 | 51% |
| 2022 | 66 | 3,128 | 54% |
| 2023 | 63 | 3,012 | 57% |
| 2024 | 54 | 3,080 | 59% |
| 2025 from claims | – | 3,114 2,857–3,294 | 59% |
| 2026 forecast | – | 3,166 2,785–3,653 | 60% |
| 2027 forecast | – | 3,216 2,749–3,832 | 60% |
| 2028 forecast | – | 3,266 2,725–4,000 | 61% |
| 2029 forecast | – | 3,317 2,709–4,160 | 61% |
| 2030 forecast | – | 3,368 2,698–4,316 | 62% |
Carotid endarterectomy and stenting including TCAR. Professional codes (what the surgeon bills): CPT 35301, 37215.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 35% of the cases CMS names in Texas; 37 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 99% inpatient hospital, 1% hospital outpatient.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Florida | 67 | 3,226−2.7%/yr | −2.7%/yr | 1.4 | 0% | 3,330 in 2030+0.5%/yr |
| Georgia | 20 | 1,108−4.6%/yr | −4.6%/yr | 1.3 | 0% | 1,310 in 2030+2.8%/yr |
| Tennessee | 23 | 1,070−7.3%/yr | −7.3%/yr | 1.5 | 0% | 1,090 in 2030+0.3%/yr |
| Virginia | 28 | 1,070−3.9%/yr | −3.9%/yr | 1.0 | 0% | 1,290 in 2030+3.1%/yr |
| North Carolina | 17 | 916−10%/yr | −10%/yr | 0.9 | 0% | 940 in 2030+0.4%/yr |
| Maryland | 19 | 887+1.4%/yr | +1.4%/yr | 1.0 | 0% | 950 in 2030+1.2%/yr |
| Kentucky | 15 | 796−5.1%/yr | −5.1%/yr | 1.7 | 0% | 760 in 2030−0.8%/yr |
| Oklahoma | 16 | 757−4.9%/yr | −4.9%/yr | 1.5 | 0% | 700 in 2030−1.3%/yr |
| South Carolina | 14 | 710−8.3%/yr | −8.3%/yr | 1.0 | 0% | 840 in 2030+2.9%/yr |
| Louisiana | 17 | 665−8.6%/yr | −8.6%/yr | 1.6 | 0% | 580 in 2030−2.4%/yr |
| Alabama | 13 | 603−11%/yr | −11%/yr | 1.3 | 0% | 600 in 2030−0.2%/yr |
| Arkansas | 13 | 532−8.8%/yr | −8.8%/yr | 1.4 | 0% | 550 in 2030+0.4%/yr |
| Mississippi | 11 | 448−8.8%/yr | −8.8%/yr | 1.2 | 0% | 340 in 2030−4.7%/yr |
| West Virginia | 5 | 402−5.6%/yr | −5.6%/yr | 1.9 | 0% | 380 in 2030−1%/yr |
| Delaware | 10 | 186−2.9%/yr | −2.9%/yr | 1.1 | 0% | 180 in 2030−0.6%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Superficial venous ablation | 220 | 22,416+0.2%/yr | +0.2%/yr | 9.91.9× | 98% | 30,300 in 2030+5.1%/yr |
| Peripheral arterial intervention | 128 | 16,813−7.6%/yr | −7.6%/yr | 7.41.2× | 58% | 19,600 in 2030+2.6%/yr |
| Dialysis access | 153 | 14,652−16%/yr | −16%/yr | 7.11.4× | 71% | 14,800 in 2030+0.2%/yr |
| Thrombectomy, IVC filters & venous stents | 30 | 4,117+1.6%/yr | +1.6%/yr | 1.91.1× | 17% | 6,020 in 2030+6.5%/yr |
| Aortic endografts (EVAR/TEVAR) | 3 | 1,065−5.8%/yr | −5.8%/yr | 0.51.1× | 0% | 1,150 in 2030+1.3%/yr |
Carotid revascularization in every state, and its device makers · Every procedure market in Texas · Every state · Compare with Florida
Boston Scientific leads with 94% of company spending on these surgeons in 2025, +12 pts on 2024.
In 2025, 7 companies reported engagement with Texas’s surgeons worth $257K in consulting, speaking, meals and travel tied to these products, about $4,764 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 19 clearances and approvals in the category, 7 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.